A Retrospective Study on Hospitalized Patients With Community-acquired Pneumonia in China (CAP-China)

Overview

The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and healthcare-associated pneumonia (HCAP) in real life of China .

Full Title of Study: “Management in Real-life of Patients Hospitalized With Community-acquired Pneumonia in China”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 2016

Detailed Description

In China, the data about current management of patients hospitalized with CAP in the real-life setting is not available,type of pneumonia, selection of initial antibiotic, time to clinical stability, antibiotic choice anf modification,clinical outcomes and costs remain unclear. In this study, we will collect comprehensive information on CAP and HCAP management patterns to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China .to analyze microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of patients with CAP (> and = 65 years, different comorbidities ,risk factors) ,to investigate microbiological characteristics,clinical manifestations,antibiotic regimens ,adherences to guidelines and effect on outcome in different groups of disease severity with CAP ,to provide the difference on microbiological characteristics,clinical manifestations,antibiotic regimens ,and outcome between patients with CAP and HCAP ,to understand the current situation of antibiotic regimen ,to evaluate influence of different antibiotic regimens on prognosis.

Interventions

  • Other: other
    • retrospective cohort study

Clinical Trial Outcome Measures

Primary Measures

  • treatment failure at 72h after initiation of antibiotics
    • Time Frame: Time from the first dose use of antibiotics to 72 hours
    • treatment failure was defined as a change of antibiotics due to worsening signs or symptoms associated with pneumonia
  • in-hospital treatment failure due to multiple causes
    • Time Frame: Time from date of admission to discharge up to 1 week
    • 1)death in hospital;2)change of antibiotics due to worsening signs or symptoms of infection, 3) recurrence, defined as signs or symptoms of infection after completion of therapy requiring re-initiation of antibiotics

Secondary Measures

  • Duration of intravenous antimicrobial therapy
    • Time Frame: 2 weeks
    • Time from the first dose of intravenous antibiotics to date of stop of intravenous antibiotics ,participants will be followed for the duration of hospital stay
  • Hospital length of stay
    • Time Frame: 2 weeks
    • Patients will be asked about hospitalization, date, Patients will be asked about hospitalization, date, participants will be asked about the time of admission and discharge
  • in-hospital mortality
    • Time Frame: 2 weeks
    • Time from date of admission to date of discharge,participants will be followed for the duration of hospital stay

Participating in This Clinical Trial

Inclusion Criteria

  • Patients > or = 14 years of age – Patient meets the criteria of community acquired pneumonia – Patient meets the criteria of healthcare-associated pneumonia Exclusion Criteria:

  • Patients <14 years of age – Patient meets the criteria of hospital acquired pneumonia – Known active tuberculosis or current treatment for tuberculosis – Non-infectious pulmonary diseases – HIV positive

Gender Eligibility: All

Minimum Age: 14 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Capital Medical University
  • Collaborator
    • Beijing Chao Yang Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Bin Cao, MD – Capital Medical University
  • Overall Official(s)
    • Bin Cao, MD, Study Chair, China-Japan Friendship Hospital
  • Overall Contact(s)
    • Bin Cao, MD, 86-010-84206264, caobin_ben@163.com

Citations Reporting on Results

Yang SQ, Qu JX, Wang C, Yu XM, Liu YM, Cao B. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period. Clin Respir J. 2014 Apr;8(2):185-91. doi: 10.1111/crj.12056. Epub 2013 Nov 26.

Cao B, Huang GH, Pu ZH, Qu JX, Yu XM, Zhu Z, Dong JP, Gao Y, Zhang YX, Li XH, Liu JH, Wang H, Xu Q, Li H, Xu W, Wang C. Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia. Chest. 2014 Jan;145(1):79-86. doi: 10.1378/chest.13-1186.

Qu J, Gu L, Wu J, Dong J, Pu Z, Gao Y, Hu M, Zhang Y, Gao F, Cao B, Wang C; Beijing Network for Adult Community-Acquired Pneumonia (BNACAP). Accuracy of IgM antibody testing, FQ-PCR and culture in laboratory diagnosis of acute infection by Mycoplasma pneumoniae in adults and adolescents with community-acquired pneumonia. BMC Infect Dis. 2013 Apr 11;13:172. doi: 10.1186/1471-2334-13-172.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.